Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IM19 chimeric antigen receptor T cell therapy - Beijing Immunochina Medical Science and Technology

Next Previous
Drug Profile

IM19 chimeric antigen receptor T cell therapy - Beijing Immunochina Medical Science and Technology

Alternative Names: IM19 CAR-T cells; IM19-CAR-T-Cells-Beijing-Immunochina-Medical-Science-and-Technology; IM19CAR-T; IM19CAR-T-Beijing-Immunochina-Medical-Science-and-Technology

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Immunochina Medical Science and Technology
  • Developer Beijing Immunochina Medical Science and Technology; Peking University Third Hospital
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Leukaemia
  • Phase I/II Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Clinical Phase Unknown Systemic lupus erythematosus
  • No development reported Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 28 Aug 2025 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in China
  • 04 Nov 2024 Beijing Immunochina Medical Science & Technology plans an early phase I trial for IgA nephropathy in November 2024 (NCT06690359)
  • 30 Jul 2024 Clinical trials in Systemic lupus erythematosus in China (IV) (NCT06513429)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top